Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • TA422
  • Published: 

History

Documents created during the development process.

Expected publication

Final appraisal determination

Invitation to participate